^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | ebvaciclib (PF-06873600) (CDK4 inhibitor, CDK6 inhibitor, CDK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of PF-06873600 in People With Cancer
Excerpt:
...- Have a diagnosis of Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer • Prior combined CDK 4/6 inhibitor and endocrine therapy and 1 or 2 prior lines of chemotherapy...
Trial ID:
Source:
Title:
A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 in Combination With Endocrine Therapy
Excerpt:
...• Have a diagnosis of Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer and prior combined CDK 4/6 inhibitor and endocrine therapy and 1 or 2 prior lines of chemotherapy (Part 2A).• Have a diagnosis of Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer and has not received a CDK 4/6 inhibitor as treatment as an adjuvant or as treatment is the advanced or metastatic setting and has also not received an aromatase inhibitor in the advanced or metastatic setting (prior adjuvant therapy with AI is permitted). ...
Trial ID:
Less C2 evidence
Source:
Title:
A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast or ovarian cancer
Published date:
10/09/2021
Excerpt:
Three heavily pre-treated pts with HR+/HER2– BC (including prior ET + CDK4/6i and Cx) treated with PF-3600 alone had partial responses (2 confirmed), including 1 pt who remained on Tx for >13 mos….PF-3600 can be combined with ET with a manageable AE profile and demonstrates promising preliminary antitumor activity in heavily pretreated pts, including those with HR+/HER2– BC progressing on ET + CDK4/6i and Cx.
